Literature DB >> 31203229

Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome.

Eloi Garcia-Vives1,2, Alfons Segarra-Medrano1,2, Ferran Martinez-Valle1,2, Irene Agraz1,2, Roser Solans-Laque3,4.   

Abstract

OBJECTIVE: To analyze the role that infections play on the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) outcome.
METHODS: A retrospective study of adult patients with AAV diagnosed in a tertiary center. Clinical features, laboratory findings, treatment, relapses, major infections, and outcome were evaluated.
RESULTS: Included were 132 patients [51 microscopic polyangiitis (MPA), 52 granulomatosis with polyangiitis (GPA), 29 eosinophilic GPA (EGPA)] with a mean followup of 140 (96-228) months. ANCA were positive in 85% of cases. A total of 300 major infections, mainly bacterial (85%), occurred in 60% patients during the followup. Lower respiratory tract (64%) and urinary tract infections (11%) were the most frequent, followed by bacteremia (10%). A total of 7.3% opportunistic infections were observed, most due to systemic mycosis. Up to 46% of all opportunistic infections took place in the first year of diagnosis, and 55% of them under cyclophosphamide (CYC) treatment. Bacterial infections were associated with Birmingham Vasculitis Activity Score (version 3) > 15 at the disease onset, a total cumulative CYC dose > 8.65 g, dialysis, and development of leukopenia during the followup. Leukopenia was the only factor independently related to opportunistic infections. Forty-four patients died, half from infection. Patients who had major infections had an increased mortality from any cause.
CONCLUSION: Our results confirm that major infections are the main cause of death in patients with AAV.

Entities:  

Keywords:  ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; INFECTIONS; SURVIVAL; VASCULITIS

Mesh:

Substances:

Year:  2019        PMID: 31203229     DOI: 10.3899/jrheum.190065

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram.

Authors:  Naidan Zhang; Jiaxiang Sun; Chaixia Ji; Xiao Bao; Chenliang Yuan
Journal:  Clin Rheumatol       Date:  2022-08-02       Impact factor: 3.650

Review 2.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

3.  Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.

Authors:  Xiaoxin Chu; Yu Hong; Yuxi Wang; Chong Yu; Lisheng Wang; Hui Tong; Jianjun Yan; Zhonghua Zhang; Gang Xu; Ying Yao; Rui Zeng
Journal:  Am J Nephrol       Date:  2021-12-07       Impact factor: 3.754

4.  Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients.

Authors:  Evangelia Argyriou; Noemin Kapsala; Konstantinos Thomas; Alexandros Panagiotopoulos; Aglaia Chalkia; Emilia Hadziyannis; Kyriaki Boki; Pelagia Katsimbri; Dimitrios T Boumpas; Panagiota Giannou; Dimitrios Petras; Dimitrios Vassilopoulos
Journal:  Arthritis Res Ther       Date:  2021-03-20       Impact factor: 5.156

5.  Outcome of Patients With Necrotizing Vasculitis Admitted to the Intensive Care Unit (ICU) for Sepsis: Results of a Single-Centre Retrospective Analysis.

Authors:  Marco Krasselt; Christoph Baerwald; Sirak Petros; Olga Seifert
Journal:  J Intensive Care Med       Date:  2020-09-02       Impact factor: 3.510

6.  The confused puzzles in antineutrophil cytoplasmic antibody-associated vasculitis activity evaluation: A case report.

Authors:  Ai-Hua Zhang; Wei-Long Yao; Wen-Hu Liu
Journal:  Clin Case Rep       Date:  2021-07-23

7.  Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.

Authors:  Kentaro Kuzuya; Takayoshi Morita; Atsushi Kumanogoh
Journal:  RMD Open       Date:  2020-04

8.  Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.

Authors:  Gwen E Thompson; Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Melissa R Snyder; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; Ulrich Specks
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.